-
Mashup Score: 12The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods - 3 month(s) ago
Atherosclerosis is a multifactorial, progressive, chronic inflammatory disease. Ultrasound and magnetic resonance imaging are the most accurate predictors of atherosclerotic plaque instability (MRI). Cytokines such as osteopontin, osteoprotegerin, and metalloproteinase 9 could be used as the most recent markers to identify and track the efficacy of anti-atherosclerotic therapy. Patients with USG and MRI-verified unstable atherosclerotic plaque were included in the study. Biomarker concentrations were measured and compared before and after PCSK9 inhibitor therapy. Additionally, concentrations prior to treatment were correlated with MRI images of the carotid artery. After treatment with alirocumab, the concentrations of MMP-9 (p < 0.01) and OPN, OPG (p < 0.05) decreased significantly. Furthermore, the results of OPN, OPG, and MMP 9 varied significantly depending on the type of atherosclerotic plaque in the MRI assay. In stable atherosclerotic plaques, the concentrations of OPN and OPG we
Source: www.mdpi.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 4
Background Information on the real‐world use of proprotein convertase subtilisin kexin 9 inhibitors (PCKS9is) in familial hypercholesterolemia are limited. We evaluated the pattern of prescription …
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 33Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World—MEMOGAL Study - 5 month(s) ago
American Journal of Cardiovascular Drugs – The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but…
Source: link.springer.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2
Corresponding Author
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 1Enquête nationale iPCSK9 – Cncf - 6 month(s) ago
Toutes les questions marquées d’une (*) sont obligatoires Vous êtes* Une femme Un homme Age* Votre spécialité* Cardiologie générale Rythmologie Cardiologie interventionnelle Insuffisance cardiaque Autre Votre durée d’exercice* < 10 ans...
Source: cncf.euCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 5Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque - 7 month(s) ago
Preclinical evidence suggests that proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors hold anti-inflammatory properties independently of their ability to lower LDL-cholesterol (C). However, whether PCSK9 inhibitors exert anti-inflammatory effects within the atherosclerotic plaque in humans is unknown. We explored the impact of PCSK9 inhibitors, used as monotherapy, compared with other lipid-lowering drugs (oLLD) on the expression of inflammatory markers within the plaque, assessing also the subsequent incidence of cardiovascular events.
Source: www.atherosclerosis-journal.comCategories: Cardiologists1, Latest HeadlinesTweet
-
Mashup Score: 6Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaque - 7 month(s) ago
Preclinical evidence suggests that proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors hold anti-inflammatory properties independently of their ability to lower LDL-cholesterol (C). However, whether PCSK9 inhibitors exert anti-inflammatory effects within the atherosclerotic plaque in humans is unknown. We explored the impact of PCSK9 inhibitors, used as monotherapy, compared with other lipid-lowering drugs (oLLD) on the expression of inflammatory markers within the plaque, assessing also the subsequent incidence of cardiovascular events.
Source: www.atherosclerosis-journal.comCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 24Concomitant Coronary Atheroma Regression and Stabilization in Response to Lipid-Lowering Therapy: - 7 month(s) ago
Abstract Background The frequency, characteristics and outcomes of patients treated with high-intensity lipid-lowering therapy and showing concomitant atheroma volume reduction, lipid content reduc…
Source: www.jacc.orgCategories: Latest Headlines, Partners & KOLsTweet
-
Mashup Score: 5Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else? - 9 month(s) ago
AbstractBackground. Familial hypercholesterolemia is the elective clinical condition that deserves the maximal personalisation in lipid-lowering therapy, especi
Source: OUP AcademicCategories: Cardiologists, Latest HeadlinesTweet
-
Mashup Score: 7
Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice
Source: www.minervamedica.itCategories: Cardiologists, Latest HeadlinesTweet
https://t.co/qom4GyjWQY #PCSK9i